FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

Home
/
update
/
details

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

NextEdge Admin

13 Nov 2024

2 min 19 sec

McKesson company,Datavant,real-world data

Ontada®, a McKesson company specializing in community oncology data, clinical education, and point-of-care technologies, has formed a strategic partnership with Datavant to expand access to Ontada’s real-world data through Datavant’s health data ecosystem. This collaboration enables life science companies to quickly access Ontada’s comprehensive data, accelerating oncology research and advancing innovative treatments for cancer patients.

Ontada’s dataset includes insights from over 2.4 million patients across 80+ tumor types through The US Oncology Network (The Network), a prominent network of community-based cancer practices. The Network treats one in five cancer patients in the U.S. and offers a unique view of community oncology care, where 85% of patients receive treatment.

“Given the increasing importance and volume of real-world data, our Life Sciences partners need efficient ways to identify suitable data sources,” said Amy O'Sullivan, Ontada’s Senior VP and Chief Research Officer. “Our partnership with Datavant accelerates the identification of data for real-world evidence generation, commercial strategies, and drug development.”

Datavant’s President, Arnaub Chatterjee, emphasized the collaboration’s potential impact: “We’re eager to combine Ontada’s community-level insights with Datavant’s extensive real-world data ecosystem to advance oncology research and speed up access to life-altering therapies for patients.”

This collaboration follows Ontada’s recent partnership with Microsoft to apply AI to unstructured healthcare data, further enhancing data utility. Through Datavant, Ontada’s partners will now have secure, tokenized access to Ontada’s representative database, maximizing data-driven insights for oncology innovation.